Detection and treatment of early stage prostate cancer. Seminar. USA, 1993/12.
Screening for prostate cancer and subsequent treatment is of uknnown benefit but carries known treatment related morbidity and mortality risks.
The recent enthusiasm for screening in the United States contrasts sharply with the more cautious attitudes of the European and Canadian medical communities.
Current data from screening series without randomization and controls are inadequate to determine screening benefit.
The prostate, lung, colorectal and ovarian cancer (randomized, controlled) screening trial of the National Cancer Institute, to include 74,000 men (and 74,000 women) 60 to 74 years old, has a design power of 90% to determine a 20% reduction of prostate cancer mortality from a baseline and 3 subsequent annual screens using prostate specific antigen and digital rectal examination.
Mots-clés Pascal : Epithélioma, Prostate, Antigène spécifique tumeur, Etats Unis, Amérique du Nord, Amérique, Dépistage, Homme, Mâle, Appareil urinaire pathologie, Prostate pathologie, Appareil génital mâle pathologie, Tumeur maligne, Exploration immunologique
Mots-clés Pascal anglais : Carcinoma, Prostate, Tumor specific antigen, United States, North America, America, Medical screening, Human, Male, Urinary system disease, Prostate disease, Male genital diseases, Malignant tumor, Immunological investigation
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0217791
Code Inist : 002B14D02. Création : 09/06/1995.